卡瑞利珠单抗联合卡培他滨用于一线治疗复发转移鼻咽癌患者 维持治疗疗效及对患者免疫功能的影响.

Objective: To investigate the efficacy of carelizumab combined with capecitabine for maintenance therapy in first-line treatment of patients with recurrent metastatic nasopharyngeal carcinoma (NPC), and its impact on immune function of patients. Methods 80 patients with recurrent metastasis of NPC who were admitted to Qinzhou First People’s Hospital from January 2020 to January 2022 were selected, the recurrent and metastatic NPC patients were divided into the control group and the observation group according to the random number table method, each group has 40 cases. Both groups received gemcitabine combined with cisplatin chemotherapy, the control group received carelizumab monotherapy maintenance treatment for 1 year after chemotherapy, and the observation group received carelizumab combined with capecitabine maintenance treatment for 1 year after chemotherapy. Differences in efficacy, adverse reactions, and percentage of B lymphocyte subsets and natural killer cells (NK) before and after treatment were compared between the two groups. Results; The objective remission rate (ORR) and disease control rate (DCR) in observation group were higher than those in control group (P＜0. 05). The percentages of CD5+B cells, CD5+CD19+B cells and CD3-CD56+NK cells in peripheral blood after treatment was decreased between the two groups (P＜0. 05), but the percentages of CD5+B cells, CD5+CD19+B cells and CD3-CD56+NK cells in peripheral blood of the observation group were higher than those of the control group after treatment (P＜0. 05). There was no significant difference in the incidence of adverse reactions above grade Ⅲ between the two groups (P＞0. 05). Conclusion: Carelizumab combined with capecitabine in first-line maintenance treatment of recurrent and metastatic NPC could improve clinical efficacy, reduce the impact on cellular immune function, and it was safe and reliable. [ABSTRACT FROM AUTHOR]